Study Comparing TAR-210 and Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer

Inclusion Criteria

• Diagnosed with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with specific tumor characteristics.
• Have a specific genetic mutation or fusion in the FGFR gene, confirmed by urine or tumor tissue testing.
• All visible tumors must be removed before starting the study, and urine tests must not show signs of high-grade cancer.
• Must have received a certain amount of BCG treatment in the past, or have been unable to complete BCG treatment due to side effects.
• Have a performance status score of 0, 1, or 2, indicating good overall health.
• Must not be eligible for or must refuse bladder removal surgery (radical cystectomy).

Exclusion Criteria

• Have had carcinoma in situ (CIS) or more advanced bladder cancer at any time.
• Have other active cancers that are progressing or have required treatment changes in the last 24 months, except for certain low-risk cancers.
• Have bladder or urethral conditions that could make it unsafe to use TAR-210.
• Have a history of excessive urination, with more than 4,000 mL of urine in 24 hours.
• Cannot have a permanent catheter, but occasional catheter use is allowed.